Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007275:Injections, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000145:classification / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D018579:Patient Selection; D012008:Recurrence; D018709:Statistics, Nonparametric; D015996:Survival Rate; D013866:Thioguanine / Q000008:administration & dosage; D013997:Time Factors
D003561:Cytarabine; D005047:Etoposide; D013866:Thioguanine; D015255:Idarubicin